Category Archives: Global

The Technologies Set to Transform Healthcare

By G. Steven Burrill, CEO, Burrill & Company. The promise of precision medicine is beginning to bear fruit as deadly diseases are made treatable, doctors use genetic information to guide treatment decisions, and the convergence of information, communications, and biological technology reinvents the practice of medicine. The arrival of this new age of medicine has […]
Also posted in Biotech, Guest Blog, healthcare, Op-Ed, Technology | Tagged , , , | Leave a comment

Strong IP Plans Essential for UK Life Sciences Clusters

By John Dean, Withers & Rogers LLP. Life sciences and biotech research clusters across the UK, including those linked to university research departments are benefiting from an improved funding climate and ongoing consolidation in the pharmaceutical sector. However, as big pharma companies increasingly vie for the best spin-out investment opportunities, those with strategic intellectual property […]
Also posted in Biotech, Europe, Guest Blog, IP, Strategy | Tagged , , , | Leave a comment

BIO 2014 Takeaway: The Peace Dividend

A surprising take away from the BIO International Convention in San Diego last month is the stark contrast between cooperative industry engagement and an unstable geopolitical order marked by xenophobia, drift and active, often violent government disengagement from the hard work of building common ground. While BIO held 29,000 partnering meetings over four days, convened […]
Also posted in Biotech, Emerging Markets, Europe, Events | Tagged , , | Leave a comment

Takeda's New Vaccines Division Charts Course to Global Growth

Today’s vaccines business represents an almost perfect world for big Pharma. There is a vast landscape of unmet medical need; lots of new science; longer product life cycles, with low exposure to post-patent generic competition; greater stability in pricing and supply commitments; more cost-effective manufacturing and delivery technologies; and the reputational gains that come from […]
Also posted in Strategy | Tagged , , | Leave a comment

EMA Delays Adoption of Policy on Publishing Trial Data

The European Medicines Agency (EMA) has postponed formal adoption of the policy on publication of clinical trial data. An EMA press statement said that “[f]urther clarifications on wording and practical arrangements will be discussed by Board members”, whose additional contributions will now be considered with a view to reaching final agreement at the Management Board meeting on 2 October. […]
Also posted in Europe, R&D, Regulatory | Tagged , | Leave a comment
  • Categories

  • Meta